1 “... intravenously as 60 mg infusions over 60 minutes daily for 10 days out of a 14-day period, followed by a 14-day...”

2 “... intravenously as 60 mg infusions over 60 minutes daily for 10 days out of a 14-day period, followed by a 14-day...”

3 “... by ixekizumab ($346,946 per QALY versus SEB infliximab). All other comparator drugs were ruled out, as they were...”

4 “... for clinicians to identify those patients most likely to benefit from extended DAPT, as well as rule out those...”

5 “... by ixekizumab ($346,946 per QALY versus SEB infliximab). All other comparator drugs were ruled out, as they were...”

6 “... for clinicians to identify those patients most likely to benefit from extended DAPT, as well as rule out those...”